<DOC>
	<DOCNO>NCT02683655</DOCNO>
	<brief_summary>The purpose study assess efficacy safety apatinib Metastatic Esophageal Cancer .</brief_summary>
	<brief_title>Study Apatinib Metastatic Esophageal Cancer</brief_title>
	<detailed_description>Eligible patient receive apatinib treatment disease progression intolerable toxicity patient withdrawal consent failure chemotherapy radiotherapy .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Age : 18 to75 year old ; 2 . Pathologically diagnosed metastatic esophageal squamous cell cancer measurable metastasis outside stomach ( measure ≥ 10mm spiral CT scan , satisfy criterion RECIST 1.1 ) ; 3 . Failed firstline chemotherapy radiotherapy treatment ; 4 . ECOG PS 01 ; 5 . An expected survival ≥ 3 month ; 6 . No treat molecularly target therapy . If receive chemotherapy , radiotherapy surgery , must ≥4 week , adverse reaction wind completely restore ; 7 . Major organ function meet follow criterion : ANC ≥ 1.5 × 109 / L ; HB ≥ 90g / L ; PLT ≥ 100 × 109 / L ; ALB≥30g / L ; TBIL≤1.5 time upper limit normal ( ULN ) ; ALT AST＜2 × ULN ; Plasma Cr＜1.5 × ULN 8 . Patient voluntarily join study sign Informed Consent Form study ; 9 . Researchers believe patient benefit ; 1 . Pts malignant tumor time past . 2 . Pregnant lactating woman ; 3 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure＞150 mmHg diastolic blood pressure＞100 mm Hg ) despite standard medical management ; Coronary heart disease great ClassII ; Echocardiography : LVEF ( LVEF ) ＜50 % ; 4 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 5 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 6 month ; 6 . Associated CNS ( central nervous system ) metastases ; 7 . Abnormal Coagulation , tendency bleed ; 8 . With psychotropic drug abuse history ca n't get rid mental disorder patient ; 9 . Anastomotic recurrence ; 10 . Participated clinical trial within 4 week ; 11 . Any condition might place patient undue risk preclude patient completing study ; 12 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>